IMGN 779

Drug Profile

IMGN 779

Alternative Names: IMGN779

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; CD33 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • Research Myelodysplastic syndromes

Most Recent Events

  • 29 Aug 2017 Jazz Pharmaceuticals and ImmunoGen agree to co-promote and co-develop IMGN 779 worldwide
  • 26 Jun 2017 Adverse events, pharmacokinetics, and pharmacodynamics data from a phase I trial in Acute myeloid leukaemia released by ImmunoGen
  • 24 Jun 2017 Updated adverse events, pharmacokinetics, and pharmacodynamics data from a phase I trial in Acute myeloid leukaemia reported at the 22nd Congress of the European Haematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top